Health Utilities in Alzheimer’s Disease and Implications for Cost-Effectiveness Analysis

Author： Neumann Peter J.  

Publisher： Adis International

ISSN： 1170-7690

Source： PharmacoEconomics, Vol.23, Iss.6, 2005-01, pp. : 537-541

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

An Outline For a Cost-Effectiveness Analysis of a Drug For Patients With Alzheimer's Disease

By Busschbach J.J.V.  

PharmacoEconomics, Vol. 13, Iss. 1 Part 2, 1998-01 ,pp. : 21-34

Adis International

Access to resources Recommend Favorite

Cost Effectiveness of Memantine in Alzheimer’s Disease: An Analysis Based on a Probabilistic Markov Model from a UK Perspective

By Roy W. Jones  

Drugs & Aging, Vol. 21, Iss. 9, 2004-01 ,pp. : 607-620

Adis International

Access to resources Recommend Favorite

Modelling Disease Progression in Alzheimer's Disease: A Review of Modelling Methods used for Cost-Effectiveness Analysis

By Green Colin  

PharmacoEconomics, Vol. 25, Iss. 9, 2007-01 ,pp. : 735-750

Adis International

Access to resources Recommend Favorite

Valuing Health States for Use in Cost-Effectiveness Analysis

By Brazier John  

PharmacoEconomics, Vol. 26, Iss. 9, 2008-01 ,pp. : 769-779

Adis International

Access to resources Recommend Favorite

Cost Effectiveness of Memantine in Moderately Severe to Severe Alzheimer’s Disease: A Markov Model in Finland

By François C.  

Clinical Drug Investigation, Vol. 24, Iss. 7, 2004-01 ,pp. : 373-384

Adis International

Access to resources Recommend Favorite